Home>Topics>Companies>Amylin Pharmaceuticals

Amylin Pharmaceuticals

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
  1. AstraZeneca's New Diabetes Drug May Also Combat Alzheimer's Disease

    Headlines

    Thu, 27 Mar 2014

    Glen S. Woods: A relatively new diabetes drug, Symlin (pramlintide), developed by AstraZeneca's ( AZN ) Amylin Pharmaceuticals has been found to combat a major component of Alzheimer's disease ( AD ) and may offer a new treatment option

  2. Human Genome and Glaxo Agree on $3.6 Billion Takeover Price Tag

    Commentary

    Mon, 16 Jul 2012

    and albiglutide, a once-weekly GLP-1 peptide that could be a more convenient alternative to Novo Nordisk's NVO and Amylin 's AMLN competing diabetes products. The diabetes and cardiovascular markets are expansive, and darapladib and albiglutide could

  3. New Morningstar Analyst Report for Amylin Pharmaceuticals Inc

    Stock Reports

    Mon, 2 Jul 2012

    Prescriptions for Amylin 's breadwinner Byetta have declined ..... entrench Victoza in the market. We think Amylin will have a hard time returning to top ..... basis for both Byetta and Bydureon, but Amylin lacks a composition-of-matter patent

  4. Bristol and Astra Announce Amylin Acquisition; Valuation Likely Unchanged for Big Pharma Firms

    Commentary

    Mon, 2 Jul 2012

    AstraZeneca AZN announced the acquisition of Amylin AMLN for $31 per share in an all-cash deal. Amylin 's board of directors unanimously recommended ..... tender their shares, so we plan to raise our Amylin fair value estimate to $31 as we don't

  5. Bydureon's Launch Doesn't Offset Declining Byetta Sales for Amylin in the First Quarter

    Commentary

    Thu, 26 Apr 2012

    Amylin AMLN saw stagnant sales and its net loss widen during first quarter ..... keeping our fair value estimate in place, which reflects Amylin 's value on a stand-alone basis. Amylin reported net product sales of $150.6 million in first

  6. Human Genome's 1Q Overshadowed by Acquisition Speculation

    Commentary

    Wed, 25 Apr 2012

    albiglutide could also hit the market within the next few years as a more convenient alternative to Novo Nordisk's NVO and Amylin 's AMLN competing diabetes products. Human Genome stands to receive royalties on worldwide sales of both products, should they become

  7. Amylin shares rise as it seeks buyers

    Headlines

    Mon, 23 Apr 2012

    (Reuters) - Shares of Amylin Pharmaceuticals Inc rose 12 percent in premarket trade following a Reuters report that the drug maker is seeking buyers after it spurned a $3.5 billion buyout offer from...

  8. Amylin Rejects $3.5 Billion Bid From Bristol; Offer Represents Premium to Firm's Stand-Alone Value

    Commentary

    Wed, 28 Mar 2012

    Shares of Amylin Pharmaceuticals AMLN skyrocketed Tuesday as it was revealed ..... our current fair value estimate for Amylin , which values the company on a stand ..... what we would expect a biotech of Amylin 's size and prospects to fetch

  9. Three Becomes Magic Number for Amylin ; Bydureon Finally Secures Approval in the U.S.

    Commentary

    Fri, 27 Jan 2012

    years in front of the Food and Drug Administration, Amylin AMLN and partner Alkermes finally succeeded in clinching approval ..... diabetes drug Bydureon, the once-weekly version of Amylin 's GLP-1 mimetic Byetta. We plan to raise our fair

  10. AMLN Under Review After Firm Calls It Quits With Longtime Partner Lilly

    Commentary

    Tue, 8 Nov 2011

    We are putting Amylin Pharmaceuticals AMLN under review following the company ..... exenatide franchise and the viability of Amylin itself has dramatically increased ..... projected modest contributions from Amylin -partnered products, and Lilly

« Prev12345Next »
Content Partners